Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264331 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KMT2ATSHRHSD17B10TDP1 | |
| SCHEMBL4261335 | 0.81 | FBP1 (0.50) | ALDH1A1KMT2ATSHRHSD17B10TDP1 | |
| SCHEMBL2801170 | 0.81 | FBP1 (0.50) | ALDH1A1KMT2ATSHRHSD17B10TDP1 | |
| SCHEMBL4261334 | 0.81 | FBP1 (0.50) | ALDH1A1KMT2ATSHRHSD17B10TDP1 | |
| SCHEMBL13232834 | 0.76 | TSHR (0.46) | ALDH1A1KMT2ATSHRHSD17B10TDP1 | |
| SCHEMBL11808459 | 0.74 | ALDH1A1 (0.54) | ALDH1A1KMT2ATSHRTDP1LMNA | |
| SCHEMBL2798947 | 0.73 | EGFR (0.48) | ALDH1A1KMT2AGAASNCALMNA | |
| SCHEMBL13232832 | 0.73 | EGFR (0.48) | ALDH1A1KMT2AGAASNCALMNA | |
| SCHEMBL2801369 | 0.73 | MAPT (0.45) | ALDH1A1KMT2AL3MBTL1LMNA | |
| SCHEMBL4264338 | 0.71 | MAPT (0.49) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | WEINER, CARL P | 2009-12-24 | — | — | US | claimed |
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | WEINER, CARL P | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | GPX1, SOD1, GPX4 | ALDH1A1 268/4885KMT2A 2739/4885TSHR 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.